Clinical characteristics and outcomes of Tafamidis-treated ATTR-CM patients in a real-world cohort: Comparison with the results of pivotal trials
Revista Portuguesa de Cardiologia · 2026-11
DOI: 10.1016/j.repc.2026.04.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Portuguesa de Cardiologia, 2026-11. Verfasst von Catarina Gregório und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Hospital de Santa Maria (ULSSM), CAML, CCUL@RISE, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
INTRODUCTION AND OBJECTIVES: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and life-threatening disease that leads to heart failure and increased mortality. Pivotal clinical trials - ATTR-ACT, ATTRibute-CM and HELIOS-B - have provided robust evidence supporting the efficacy of TTR stabilizers (Tafamidis and Acoramidis) and the TTR-synthesis inhibitor Vutrisiran in reducing mortality and cardiovascular events. This study aims to compare the clinical characteristics and cardiovascular outcomes of a real-world Portuguese cohort of patients with ATTR-CM treated with tafamidis to those reported in pivotal clinical trials. METHODS: Single-center, observational study including consecutive patients with ATTR-CM treated with tafamidis 61 mg once a day. Clinical, laboratory, and echocardiographic data were collected and compared with published results from the ATTR-ACT, ATTRibute-CM, and HELIOS-B trials. The primary endpoint was all-cause mortality at 24 months, assessed by Kaplan-Meier survival analysis. Secondary outcomes included cardiovascular-related hospitalizations and quality of life, assessed by KCCQ-OS during follow-up, both of which were compared across studies. RESULTS: A total of 89 patients were included (76 males; 39 with hereditary ATTR-CM and 50 with wild-type ATTR-CM). The Portuguese real-world cohort was older than the ATTR-ACT and HELIOS-B study populations (mean age 78.6 vs. 74.5 vs. 77.0 years, respectively; p 0.05). Hereditary ATTR was significantly more prevalent in the Portuguese cohort (44%) compared to ATTR-ACT (24%), ATTRibute-CM (10%), and HELIOS-B (11%; p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Hospital de Santa Maria (ULSSM), CAML, CCUL@RISE, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
- Department of Cardiology, hATTR Reference Centre, Hospital de Santa Maria (ULSSM), CAML, CCUL@RISE, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
- Department of Cardiology, Hospital de Santa Maria (ULSSM), CAML, CCUL@RISE, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal; Centro de Estudos de Medicina Baseada na Evidência (CEMBE), Faculdade de Medic…
- Association for Research and Development of Faculty of Medicine (AIDFM), Cardiovascular Research Support Unit (GAIC), Lisbon, Portugal.
- Neurology department, hATTR Reference Centre, Hospital de Santa Maria (ULSSM), CAML, CCUL@RISE, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
- Department of Cardiology, Hospital de Santa Maria (ULSSM), CAML, CCUL@RISE, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. Electronic address: dulce.brito@ulssm.min-saude.pt.
Zitieren
APA
Gregório, C., Agostinho, J. R., Caldeira, D., Vilela, M., Abrantes, A., Batista, M., Abrantes, F., Garcia, A. B., Campos, C., Conceição, I., Pinto, F. J., & Brito, D. (2026). Clinical characteristics and outcomes of Tafamidis-treated ATTR-CM patients in a real-world cohort: Comparison with the results of pivotal trials. Revista Portuguesa de Cardiologia. https://doi.org/10.1016/j.repc.2026.04.011
Vancouver
Gregório C, Agostinho JR, Caldeira D, Vilela M, Abrantes A, Batista M, et al. Clinical characteristics and outcomes of Tafamidis-treated ATTR-CM patients in a real-world cohort: Comparison with the results of pivotal trials. Revista Portuguesa de Cardiologia. 2026. doi:10.1016/j.repc.2026.04.011
BibTeX
@article{Gregrio2026,
author = {Gregório, Catarina and Agostinho, João R and Caldeira, Daniel and Vilela, Marta and Abrantes, Ana and Batista, Margarida and Abrantes, Filipa and Garcia, Ana Beatriz and Campos, Catarina and Conceição, Isabel and Pinto, Fausto J and Brito, Dulce},
title = {Clinical characteristics and outcomes of Tafamidis-treated ATTR-CM patients in a real-world cohort: Comparison with the results of pivotal trials},
journal = {Revista Portuguesa de Cardiologia},
year = {2026},
doi = {10.1016/j.repc.2026.04.011}
}
EUVIMED